Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Connolly

Showing results (891-900 of 1,370) with videos related to

Pageof 137
Sort By:
Journal of Thrombosis and Haemostasis : JTH|October 7, 2011
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trialK-H Liesenfeld, T Lehr, C Dansirikul, et al.
American Heart Journal|May 3, 2005
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial FibrillationCharles R Kerr, Karin H Humphries, Mario Talajic, et al.
American Journal of Human Genetics|October 27, 1997
Deletion of RB exons 24 and 25 causes low-penetrance retinoblastomaR Bremner, D C Du, M J Connolly-Wilson, et al.
Circulation|May 23, 2001
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcomeK H Humphries, C R Kerr, S J Connolly, et al.
Oncogene|October 12, 2011
A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumorsE C Piccione, T J Lieu, C F Gentile, et al.
The Canadian Journal of Cardiology|May 25, 2013
Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT)Stuart J Connolly, Francois Philippon, Yves Longtin, et al.
Journal of the American College of Cardiology|October 1, 2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)Paul A Reilly, Thorsten Lehr, Sebastian Haertter, et al.
The Lancet. Neurology|March 21, 2014
Embolic strokes of undetermined source: the case for a new clinical constructRobert G Hart, Hans-Christoph Diener, Shelagh B Coutts, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2018
Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeonsEmilie P Belley-Cote, Rohit K Singal, Graham McClure, et al.
Heart (British Cardiac Society)|May 6, 2014
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
Pageof 137

Showing results (891-900 of 1,370) with videos related to

Sort By:
Pageof 137
Journal of Thrombosis and Haemostasis : JTH|October 7, 2011
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trialK-H Liesenfeld, T Lehr, C Dansirikul, et al.
American Heart Journal|May 3, 2005
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial FibrillationCharles R Kerr, Karin H Humphries, Mario Talajic, et al.
American Journal of Human Genetics|October 27, 1997
Deletion of RB exons 24 and 25 causes low-penetrance retinoblastomaR Bremner, D C Du, M J Connolly-Wilson, et al.
Circulation|May 23, 2001
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcomeK H Humphries, C R Kerr, S J Connolly, et al.
Oncogene|October 12, 2011
A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumorsE C Piccione, T J Lieu, C F Gentile, et al.
The Canadian Journal of Cardiology|May 25, 2013
Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT)Stuart J Connolly, Francois Philippon, Yves Longtin, et al.
Journal of the American College of Cardiology|October 1, 2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)Paul A Reilly, Thorsten Lehr, Sebastian Haertter, et al.
The Lancet. Neurology|March 21, 2014
Embolic strokes of undetermined source: the case for a new clinical constructRobert G Hart, Hans-Christoph Diener, Shelagh B Coutts, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2018
Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeonsEmilie P Belley-Cote, Rohit K Singal, Graham McClure, et al.
Heart (British Cardiac Society)|May 6, 2014
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
Pageof 137